[18F]FluorThanatrace

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug Name[18F]FluorThanatrace
Drug Alias Name[18F]FluorThanatrace[18F]FTT
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18FDiagnostic agent (In vivo) > Radionuclide Imaging agent +[5] 
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWashington UniversityUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterUniversity Of WashingtonUniversity Of Pennsylvania
Inactive CompaniesWashington University School Of Medicine
Active IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Neoplasms +[11] 
Inactive IndicationsGlioblastomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A